Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years

Health Research Policy and Systems

Sun-Young Jung¹  Seung-Hun You²  Uy Dong Sohn³  Changone Kim⁴  Sora Lee⁵  Heesang Lee⁵  Seung In Um⁶ 

[1] College of Pharmacy, Chung-Ang University, Seoul, South Korea;Department of Global Innovative Drugs, Chung-Ang University, Seoul, South Korea;Department of Pharmacology, Chung-Ang University, Seoul, South Korea;Graduate School of Global Entrepreneurship, Keimyung University, Daegu, South Korea;Graduate School of Management of Technology, Sungkyunkwan University, Suwon, South Korea;Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Seoul, South Korea;

关键词: Pharmaceutical industry;    Innovation;    Regulations;    Patent;    GMP;    Drug pricing system;   

DOI  :  10.1186/s12961-021-00797-9

来源: Springer

【 摘 要 】

BackgroundThe pharmaceutical industry is heavily regulated. Partly for this reason, new drugs generally take over 10 years from the product development stage to market entry. Although regulations affect the pharmaceutical industry over a long period, previous studies investigating the impact of new regulatory policies have usually focused on the short period before and after implementing that policy. Therefore, the purpose of this study is to examine whether and how significantly regulatory policies affect long-term innovation in the pharmaceutical industry in Korea.MethodsThis study focused on three significant regulatory policies: the introduction of the product patent system, changes in the Good Manufacturing Practice (GMP) system, and the Drug Expenditure Rationalization Plan (DERP). The study used interrupted time series (ITS) analysis to investigate the long-term impacts of the policies before and after implementation.ResultsOur results show that introducing the product patent system in 1987 significantly increased the number of Korean patent applications. The effect of the revised GMP policies was also statistically significant, both before and after implementation and between pre-emptive companies and non-pre-emptive ones. However, due to the companies' negotiations with the regulatory authorities or the regulatory system that links drug approval and price evaluation, the DERP did not significantly delay new drug registration in Korea.ConclusionThis study showed that the policies of the product patent system, GMP policies, and DERP regulations have significantly encouraged pharmaceutical companies to strive to meet regulatory requirements and promote innovation in Korea. The study suggests that it is necessary for companies to pre-emptively respond to systemic changes in development and production strategies to deal with regulatory changes and achieve sustainable growth. Also, our study results indicate that since government policies motivate the innovative system of the pharmaceutical industry, governmental authorities, when formulating pharmaceutical policies, need to consider the impact on the long-term innovation of the industry.

【 授权许可】

CC BY